Nature’s Built-In Antidote
University of Maryland researchers have discovered a radical new approach to treating snakebites by harnessing the same toxin-blocking proteins snakes use to protect themselves. By combining specific blood proteins from western diamondback rattlesnakes, scientists achieved unprecedented neutralizing power against the venom of multiple dangerous species.
The breakthrough was published on July 29, 2026, in the Proceedings of the National Academy of Sciences. Led by Sean B. Carroll, Professor of Biology at UMD, the research offers a blueprint for creating far more potent and scalable treatments for lethal snakebites.
“This is one of those great stories when nature has already solved a problem we’ve been grappling with for decades,” said Carroll, who also holds the Andrew and Mary Balo and Nicholas and Susan Simon Endowed Chair at UMD.
An Outdated and Flawed Treatment Model
Snakebites remain a severely neglected tropical disease. The World Health Organization reports that venomous bites kill between 80,000 and 140,000 people annually, leaving hundreds of thousands more permanently disabled. Many victims reside in remote, rural areas with zero access to immediate care.
Current antivenoms are manufactured by immunizing large animals, like sheep or horses, with snake venom and harvesting their antibodies. This century-old method is incredibly expensive, wildly inconsistent in quality, and often triggers severe immune reactions in human patients.
These severe limitations pushed researchers to look for a better solution directly at the source. “We’ve known from anecdotes for 100 years that vipers tend to be resistant to their own venom,” Carroll explained. “But for a long time, nobody knew what exactly was circulating in their blood that protected them.”
Isolating the Snake’s Defenses
In 2022, Carroll’s lab pinpointed a critical piece of the puzzle: a single protein called FETUA-3. This protein successfully blocked the activity of various metalloproteinase toxins found in the western diamondback’s venom, as well as toxins from several other rattlesnake species.
“Here was evolution’s way for snakes to protect themselves from accidental self-envenomation,” Carroll noted. This realization sparked an obvious follow-up question. “Why rely on horse antibodies when nature has packaged an effective antidote right there in the snake?”
Perfecting the Protein Mix
For the latest study, Carroll’s team collaborated with Elda Sánchez, director of the National Natural Toxins Research Center at Texas A&M University-Kingsville. They closely investigated the individual roles of all FETUA proteins.
The researchers determined that while one FETUA protein might reduce bleeding and another might alter enzyme activity, no single protein could completely prevent death from a bite. However, when multiple FETUA proteins were combined, their ability to neutralize the venom skyrocketed.
A single venom strike can contain 100 distinct toxin proteins from various families, and no two species carry the exact same venom profile. “The ingredients are there,” Carroll said. “We just have to keep testing various mixtures.”
A 10x Leap in Potency
Lab tests proved that optimized protein combinations are roughly 10 times more potent than the current sheep-derived rattlesnake antivenoms. The new mixture completely neutralized the lethality of rattlesnake venom and offered broad protection against venoms from multiple viper species—even those separated by millions of years of evolution.
“The fact that parts of these inhibitors have been perfectly conserved over 50 million years of snake evolution tells you just how real a risk this is for these animals,” Carroll said. He added that the exact ways snakes accidentally envenomate themselves—whether through mouth tissue, cannibalism, or eating envenomated prey—remains poorly understood.
Scaling Up for Global Impact
With metalloproteinases successfully neutralized, the team is now applying this strategy to other major venom toxin families. “We’re getting remarkably close to having effective solutions for the three major toxin families in vipers,” Carroll noted.
The goal is to develop nature-based recombinant, or lab-produced, antivenoms. Carroll predicts the first commercial applications will be veterinary, eventually paving the way for safer, more affordable human treatments.
“We could make train cars’ worth of this stuff and help solve a massive global health problem,” Carroll said. “Many of our most important medicines have come from nature. I’m delighted that the components for a better-than-commercial antivenom were in these snakes all along.”
